Opthea Limited (Opthea), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), announced the appointment of Sujal Shah to the Company’s Board of Directors, effective April 4, 2024. Concurrent with his appointment as non-Executive Director, Shah will also become Chairman of the […]
about people, work, and workplaces